TimesSquare Capital Management LLC Acquires 42,830 Shares of Shockwave Medical, Inc. (NASDAQ:SWAV)

TimesSquare Capital Management LLC raised its holdings in Shockwave Medical, Inc. (NASDAQ:SWAV) by 22.8% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 230,685 shares of the company’s stock after acquiring an additional 42,830 shares during the quarter. TimesSquare Capital Management LLC’s holdings in Shockwave Medical were worth $43,959,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Robbins Farley lifted its position in shares of Shockwave Medical by 1.0% during the fourth quarter. Robbins Farley now owns 4,542 shares of the company’s stock valued at $866,000 after buying an additional 45 shares during the last quarter. Lindbrook Capital LLC boosted its holdings in Shockwave Medical by 64.8% in the third quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock valued at $30,000 after purchasing an additional 59 shares during the last quarter. Treasurer of the State of North Carolina raised its position in Shockwave Medical by 0.4% during the third quarter. Treasurer of the State of North Carolina now owns 16,390 shares of the company’s stock valued at $3,263,000 after acquiring an additional 60 shares in the last quarter. First Horizon Advisors Inc. lifted its stake in shares of Shockwave Medical by 23.1% in the 3rd quarter. First Horizon Advisors Inc. now owns 437 shares of the company’s stock valued at $87,000 after purchasing an additional 82 shares during the period. Finally, Spire Wealth Management boosted its stake in shares of Shockwave Medical by 3.9% during the 3rd quarter. Spire Wealth Management now owns 2,655 shares of the company’s stock worth $529,000 after acquiring an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 95.35% of the company’s stock.

Insiders Place Their Bets

In related news, insider Isaac Zacharias sold 4,000 shares of Shockwave Medical stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $287.67, for a total value of $1,150,680.00. Following the completion of the transaction, the insider now directly owns 56,818 shares in the company, valued at $16,344,834.06. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider Isaac Zacharias sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 26th. The shares were sold at an average price of $287.67, for a total value of $1,150,680.00. Following the sale, the insider now owns 56,818 shares of the company’s stock, valued at $16,344,834.06. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Laura Francis sold 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, March 26th. The stock was sold at an average price of $300.00, for a total transaction of $450,000.00. Following the transaction, the director now owns 3,551 shares of the company’s stock, valued at approximately $1,065,300. The disclosure for this sale can be found here. Insiders have sold a total of 83,120 shares of company stock worth $21,319,021 in the last ninety days. 3.40% of the stock is owned by corporate insiders.

Shockwave Medical Trading Down 0.0 %

Shares of NASDAQ SWAV traded down $0.09 during mid-day trading on Thursday, reaching $330.54. 506,735 shares of the company’s stock were exchanged, compared to its average volume of 924,207. The company has a debt-to-equity ratio of 1.09, a quick ratio of 10.73 and a current ratio of 11.76. The firm has a market capitalization of $12.40 billion, a price-to-earnings ratio of 85.43, a PEG ratio of 2.46 and a beta of 0.88. Shockwave Medical, Inc. has a 52-week low of $157.00 and a 52-week high of $331.58. The company’s 50-day moving average is $305.74 and its 200-day moving average is $240.67.

Shockwave Medical (NASDAQ:SWAV) last released its earnings results on Monday, May 6th. The company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.45. The company had revenue of $218.80 million during the quarter, compared to the consensus estimate of $207.69 million. Shockwave Medical had a return on equity of 23.97% and a net margin of 20.17%. Shockwave Medical’s revenue was up 35.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.03 EPS. Analysts expect that Shockwave Medical, Inc. will post 4.94 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SWAV has been the subject of several recent analyst reports. Wells Fargo & Company boosted their price target on shares of Shockwave Medical from $200.00 to $210.00 and gave the stock an “equal weight” rating in a report on Friday, February 16th. Piper Sandler raised their target price on shares of Shockwave Medical from $290.00 to $360.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 2nd. Needham & Company LLC restated a “hold” rating on shares of Shockwave Medical in a research report on Friday, April 5th. Leerink Partnrs downgraded Shockwave Medical from an “outperform” rating to a “market perform” rating in a research report on Friday, April 5th. Finally, Canaccord Genuity Group restated a “hold” rating and issued a $335.00 target price (up from $263.00) on shares of Shockwave Medical in a report on Friday, April 5th. Ten research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $309.11.

Shockwave Medical Company Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.